Track LQDA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$8.09B
Enterprise Value$8.09B
Revenue (TTM)$158.32M
Net Income (TTM)-$68.92M
Free Cash Flow (TTM)-$40.02M
Financial Health
Cash$190.68M
Net Debt$1.15M
Debt Ratio0.58
Debt to Equity4.29
Interest Coverage2.87
Valuation (TTM)
Price to Sales51.12
Price to Earnings-117.42
EV to EBITDA-180.31
Price to Book180.86
Price to Free Cash Flow-202.22
Margins (TTM)
Gross Profit Margin97.21%
EBITDA Margin-28.35%
Operating Income Margin-32.45%
Net Income Margin-43.53%
Free Cash Flow Margin-25.28%
Returns (5Y Avg)
Return on Invested Capital-44.23%
Return on Assets-37.55%
Return on Equity-117.42%
Return on Total Capital-44.23%
Return on Capital Employed-47.19%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue192.49%
Diluted EPS13.17%
Total Debt74.43%
Capital Expenditures41.96%
Free Cash Flow6.06%
CAGR (3Y)
Revenue114.98%
Diluted EPS-0.62%
Total Debt109.17%
Capital Expenditures94.20%
Free Cash Flow-5.52%
CAGR (1Y)
Revenue1000.00%
Diluted EPS85.09%
Total Debt65.65%
Capital Expenditures-12.39%
Free Cash Flow1000.00%
$80.89+$3.81|+4.94%
52W High$82.96
52W Low$14.42
50D SMA$68.28
200D SMA$42.41
Volume1.07M
Liquidia Technologies Inc
419 Davis Drive, Morrisville, NC, United States, 27560
IPO
2018
Employees
216
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 202617-17
0
Q1 20263-3
0
2-quarter cumulative
20 sells0 buys
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0